Taisho Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Co., Ltd. logo
πŸ‡―πŸ‡΅Japan
Ownership
Subsidiary
Employees
5.6K
Market Cap
-
Website
http://www.taisho.co.jp
Clinical Trials
Related News

A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

First Posted Date
2024-12-20
Last Posted Date
2024-12-20
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
100
Registration Number
NCT06745531
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Phase 2 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis with Phosphate Binders

Phase 2
Not yet recruiting
Conditions
Hyperphosphatemia Patients on Hemodialysis
Interventions
Drug: TS-172
Drug: Placebo
First Posted Date
2024-12-20
Last Posted Date
2024-12-20
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
50
Registration Number
NCT06745518
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Mass Balance Study of TS-172 in Healthy Adult Subjects

Phase 1
Completed
Conditions
Healthy Male Subjects
Interventions
Drug: [14C] TS-172
First Posted Date
2024-09-19
Last Posted Date
2024-11-13
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
6
Registration Number
NCT06596356
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Study to Investigate the Next-day Residual Effects of TS-142 in Healthy Elderly Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
Drug: Placebo
Drug: TS-142
Drug: Zopiclone
First Posted Date
2023-04-19
Last Posted Date
2023-09-05
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
43
Registration Number
NCT05819710
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Food Effect Study of TS-142 in Healthy Subjects

Phase 1
Completed
Conditions
Effect of Food
Interventions
Drug: TS-142 10 mg
First Posted Date
2023-02-01
Last Posted Date
2023-04-07
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
12
Registration Number
NCT05707897
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

First Posted Date
2023-01-26
Last Posted Date
2024-01-17
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
326
Registration Number
NCT05699239
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Pharmacokinetic Study of TS-142 in Patients With Hepatic Impairment

First Posted Date
2022-11-22
Last Posted Date
2023-12-11
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
84
Registration Number
NCT05624944
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Long-Term Study of TS-142 in Patients With Insomnia

Phase 3
Completed
Conditions
Patients With Insomnia
Interventions
Drug: TS-142 10 mg
Drug: TS-142 5 mg
First Posted Date
2022-07-18
Last Posted Date
2024-03-19
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
401
Registration Number
NCT05461352
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

Phase III Study of TS-142 in Patients With Insomnia

First Posted Date
2022-07-12
Last Posted Date
2023-12-19
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
1155
Registration Number
NCT05453136
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Tokyo, Japan

A Phase I Study of TS-172 in Healthy Adult Subjects (Single and Multiple Doses)

Phase 1
Completed
Conditions
Healthy Adult Subjects
Interventions
Drug: TS-172
Drug: Placebo
First Posted Date
2021-07-28
Last Posted Date
2022-10-06
Lead Sponsor
Taisho Pharmaceutical Co., Ltd.
Target Recruit Count
41
Registration Number
NCT04979572
Locations
πŸ‡―πŸ‡΅

Taisho Pharmaceutical Co., Ltd selected site, Toshima-ku, Japan

Β© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy